aspirin + recombinant tissue plasminogen activator

Aspirin + recombinant tissue plasminogen activator is a combination therapy involving the antiplatelet agent aspirin (acetylsalicylic acid) and the thrombolytic agent recombinant tissue plasminogen activator (rtPA), most commonly alteplase. Aspirin inhibits platelet aggregation by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 synthesis and preventing clot formation. Recombinant tissue plasminogen activator is a serine protease that catalyzes the conversion of plasminogen to plasmin, leading to fibrinolysis and dissolution of blood clots. This combination has been studied primarily in the context of acute ischemic stroke. While both agents are effective individually—rtPA for acute clot lysis within 3–4.5 hours of symptom onset and aspirin for secondary prevention—their concurrent use in the acute setting increases the risk of symptomatic intracranial hemorrhage without improving clinical outcomes compared to rtPA alone[3][4]. Current guidelines recommend against administering antiplatelet agents such as aspirin within 24 hours after intravenous thrombolysis with rtPA due to this elevated bleeding risk[3][7]. However, patients who were already on chronic aspirin therapy prior to stroke may still be eligible for rtPA if other criteria are met[7].

Other names

acetylsalicylic acid + rtPAaspirin + rtPAaspirin + alteplaseASA + recombinant tissue plasminogen activator